Business Context and Reporting Period
This Form 8-K is filed by ReShape Lifesciences Inc. (trading symbol: RSLS) on November 25, 2024. The company is incorporated in Delaware and its common stock is listed on the Nasdaq Capital Market. The filing addresses a specific regulatory notice received regarding continued listing compliance.
Key Financial Metrics
The filing provides limited financial data, specifically regarding stockholders' equity as of the most recent quarter end.
- Stockholders' Equity: $1,487,000 (as of September 30, 2024).
- Revenue, Profit, Cash Flow, Debt: The filing text does not provide clear values for these metrics.
Material Changes and Listing Status
On November 25, 2024, the Company received a written notice from the Nasdaq Staff indicating non-compliance with Nasdaq Listing Rule 5550(b)(1). This rule requires companies on the Nasdaq Capital Market to maintain a minimum of $2.5 million in stockholders' equity. The Company's equity of $1.487 million falls below this threshold.
Outlook, Management Commentary, and Risks
Compliance Timeline: The Company has 45 calendar days from the date of the notice to submit a plan to regain compliance. If the plan is accepted, Nasdaq may grant an extension of up to 180 calendar days to evidence compliance.
Management Action: Management intends to actively monitor performance regarding listing standards and will consider available options to resolve the deficiency.
Risks: Failure to regain compliance within the allotted timeframe could result in delisting from the Nasdaq Capital Market.
Investor Verification Checklist
- Verify the current stock price and market capitalization to assess the severity of the equity deficiency.
- Monitor the Company's submission of a compliance plan within the 45-day window.
- Review upcoming quarterly reports for updates on stockholders' equity and potential capital raising activities.
- Check for any subsequent 8-K filings regarding the acceptance or rejection of the compliance plan by Nasdaq.